Apexigen, Inc.
Apexigen, Inc. (APGN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
apgn · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Apexigen, Inc.You APGN | $10M | N/A | — | — |
 Allena Pharmaceuticals, Inc. ALNA | $0M | N/A | — | -$1.03 |
 Applied Molecular Transport Inc. AMTI | $11M | N/A | — | -$3.23 |
 Axcella Health Inc. AXLA | $13M | N/A | — | -$1.27 |
 Boston Therapeutics, Inc. BTHE | $0M | N/A | — | -$0.01 |
 Channel Therapeutics Corporation CHRO | $9M | N/A | — | -$2.30 |
 IMV Inc. IMVIF | $0M | N/A | — | -$4.37 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Apexigen, Inc. (APGN) measures how much investors pay for each dollar of the company's trailing earnings. APGN's current PE ratio of N/A is calculated by dividing its stock price of $0.39 by its TTM earnings per share of —.
Frequently asked questions
APGN pe ratio · 6 questionsAPGN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.39 and TTM EPS of —. Data sourced from Financial Modeling Prep via APGN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Apexigen, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09